The Marijuana Stock Price Prediction Every Investor Needs to See in 2019

marijuana stock price predictionIn a wave of momentum, marijuana legalization is becoming the standard in many U.S. states and across Canada.

It's creating a windfall for marijuana stocks, and today, we have a marijuana stock price prediction that every investor needs to see.

You see, the more states that legalize cannabis, the more people will buy it. That means skyrocketing sales for marijuana companies. In 2018, the cannabis market was worth sales of $10 billion. By the end of 2021, sales are forecast to reach $24.5 billion.

Of course, this is all extremely good news for cannabis stock prices.

THREE STOCKS: Any one of these cannabis companies could potentially deliver a 1,000% windfall. Click here to learn more...

In other words, sales are projected to rise a whopping 145% in only four years. Investing in the top marijuana stocks has the potential to change your life.

Now, some investors are still reluctant to purchase pot stocks. States have legalized it, and so have entire nations like Canada. But it still isn't legal nationwide in the United States, and it's still considered illegal under federal law.

In addition, the Trump administration isn't always clear on its stance toward legal cannabis. Last year, U.S. President Donald Trump threw support behind a bill that stopped the Drug Enforcement Administration (DEA) and the Department of Justice (DoJ) from taking action against U.S. marijuana companies, as long as their actions were within the law.

But Jeff Sessions, his one-time attorney general, wanted U.S. agencies to go after cannabis companies more aggressively. To that end, his tenure saw the end of a rule enacted during the Obama administration that supported easing toward marijuana companies.

So there's not a clear signal for cannabis stock investors emanating from the federal government.

Plus, many cannabis stocks are also penny stocks (those that trade at $5 per share or less). Penny stocks are a risky asset class with high volatility. Historically, some penny stocks are scams, set up to defraud public shareholders.

It's important to do extra research when investing in these types of stocks. Fortunately, we've done that research for you...

In fact, we have a marijuana stock price prediction today for one of the best cannabis companies in the world.

It's a venerable company that has existed for 30 years. Its shares are listed on a major exchange.

It's engaged in biopharmaceutical research. The research is looked upon favorably by the United States government - one of the few pot companies to have elicited positive attention.

We think this stock could easily return double- or even triple-digit gains for investors...

Our Marijuana Stock Price Prediction No Investor Can Afford to Miss

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

The company is GW Pharmaceuticals Plc. (NASDAQ: GWPH), a UK-based pharmaceutical firm founded in 1998.

It's engaged in the development and marketing of marijuana-based solutions for rare medical conditions. Currently, it focuses on medications for patients who are vulnerable to seizures.

GW had a major win last year when its primary drug, Epidiolex, won approval from the U.S. Food and Drug Administration (FDA).

It marked the first time that a marijuana-derived product received FDA approval for treatment of a condition within the United States. The company has reason to be proud.

The researchers at GW used cannabidiol (CBD) that was modified chemically in the development of Epidiolex. CBD is a cannabis compound. It's different from THC, which is the part of the marijuana plant that produces a "high" feeling.

Epidiolex is focused on treating two conditions that cause seizures. But it will also be researched to see if it can be applied to other medical conditions in the future.

In June 2018, for example, Epidiolex won FDA approval for treating two early-onset types of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.

Several months after that, the FDA said it was going to classify Epidiolex as a Schedule 5 drug. The Controlled Substance Act classifies drugs as certain schedules; Schedule 5 means that it is neither addictive nor dangerous.

Epidiolex is available in the United States by prescription now and has been available in pharmacies since October 2018.

Last September, the shares hit $179.65, which turned out to be the high for the year.

With the market slump, the shares have had a haircut to the current price of $125.34. But that's an excellent buying opportunity given our marijuana stock price prediction.

Money Morning Defense and Tech Specialist Michael A. Robinson believes that revenue for GWPH could skyrocket to $1.7 billion by 2026 on Epidiolex sales alone.

Currently, the market capitalization is more than $4 billion, highly impressive for a cannabis stock. It also has future plans to research additional solutions based on marijuana.

The target price for GWPH is $227. From today's price, that's a marijuana price prediction of a whopping 81% gain in just a year.

These 3 Stocks Are the Key to 2018's Greatest Profits

The 2018 midterm election was a turning point for the cannabis industry.

We expect nothing short of historic profits by the end of the year.

But not all pot stocks will hand you life-changing wins. In fact, often the companies making headlines are least likely to see the biggest gains.

These three stocks, on the other hand, are flying under the radar... for now. Each of them could see exponential stock price acceleration at any moment, and if you get in before that happens, you could turn a token stake into a lifetime of wealth.

I don't know of any other sector providing anywhere near this level of growth now.

Click here to learn more.

Follow Money Morning onFacebook, Twitter, and LinkedIn.